Oramed Pharmaceuticals Inc. (ORMP) News
Filter ORMP News Items
ORMP News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest ORMP News From Around the Web
Below are the latest news stories about ORAMED PHARMACEUTICALS INC that investors may wish to consider to help them evaluate ORMP as an investment opportunity.
3 US Penny Stocks With Market Caps Above $40MAs major U.S. stock indices reach new highs, buoyed by robust tech earnings and positive economic signals from the Federal Reserve, investors are exploring diverse opportunities across the market spectrum. Penny stocks, though often overlooked and considered a relic of past market trends, continue to attract attention due to their potential for growth within smaller or newer companies. By examining those with solid financial foundations, investors can uncover promising opportunities that... |
ORMP: Preparations for New Phase 3 Trial Advance, While ORMP Leverages Balance Sheet Through Recent AgreementsBy M. Marin NASDAQ:ORMP READ THE FULL ORMP RESEARCH REPORT Planning Phase 3 Oral Insulin study under revised protocol, new CRO agreement in place Oramed Pharmaceuticals (NASDAQ:ORMP) has pivoted its clinical R&D focus to prioritize studying ORMD 0801 for subpopulations of patients with pooled specific parameters who responded well to oral insulin in its prior trial. The subpopulation included |
US Penny Stocks To Watch: 3 Picks With Market Caps Over $40MAs the U.S. stock market experiences a rally led by the technology sector, investors are closely monitoring developments such as the presidential election and upcoming Federal Reserve decisions on interest rates. In this context, penny stocks continue to capture attention for their potential to offer both affordability and growth opportunities, despite being considered a somewhat outdated term. These smaller or newer companies can provide unique investment prospects when they demonstrate... |
Scilex Holding Starts $50 Million Registered Direct Offering of Convertible NotesScilex Holding Starts $50 Million Registered Direct Offering of Convertible Notes |
Oramed Pharmaceuticals Announces Restructuring of Scilex Holding Company DebtOramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) ("Oramed"), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today announced the execution of definitive agreements for the restructuring of a portion of its existing Senior Secured Promissory Note from Scilex Holding Company (Nasdaq: SCLX) ("Scilex"), a company focused on non-opioid pain management products. |
ORMP: Balance Sheet Strong, Potential Benefits of Investments, JVs, BuybacksBy M. Marin NASDAQ:ORMP READ THE FULL ORMP RESEARCH REPORT Solid cash & equivalents position as former CFO resumes role… Oramed Pharmaceuticals (NASDAQ:ORMP) has named its former Chief Financial Officer to the CFO position again. In June 2024, the company named Avraham Gabay as CFO, Secretary and Treasurer to replace former CFO David Silberman. Mr. Silberman had announced his intention to |
Oramed: Q2 Earnings SnapshotNEW YORK (AP) — Oramed Pharmaceuticals Inc. ORMP) on Wednesday reported earnings of $9.2 million in its second quarter. The New York-based company said it had profit of 22 cents per share. |
3 Micro-Cap Moonshots for Fearless InvestorsWhen discussing micro-cap stocks, it’s important to recognize their general overlap with the world of penny stocks. These stocks trade as shares of companies with market capitalizations between $50 million and $300 million. While those numbers may sound worthy to the individual investor, they represent a generally risky position for a handful of reasons. The first is that micro-cap stocks are often derived from young and relatively unproven companies. Just because a company publicly trades on th |
Oramed Letter to ShareholdersOramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) ("Oramed") (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today issued a Letter to Shareholders from its Chief Executive Officer, Nadav Kidron. |
Oramed Pharmaceuticals Inc. Announces the Buy-Back of its Common StockOramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (the "Company") (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today announced today that its Board of Directors has authorized a common stock repurchase plan allowing for the buy-back of up to $20,000,000 in maximum value of its common stock through open market purchases, privately-negotiated transactions, or otherwise in compliance with Rule 10b-18 under the Securities |